Literature DB >> 27297083

A Rare Case of Embolic ST-Elevation Myocardial Infarction in an Adult Patient With Repaired Hypoplastic Left Heart Syndrome.

Razan Shamoon1, Habib Habib2, Upamanyu Rampal3, Aiman Hamdan2, Mahesh Bikkina2, Fayez Shamoon2.   

Abstract

A 24-year-old male with past medical history of hypoplastic left heart syndrome and staged reconstructive surgery in infancy culminating in the Fontan circulation presented to the hospital with a chief complaint of chest pain described as an "elephant sitting" on his chest. Initial 12-lead electrocardiogram revealed 2-mm ST segment elevation in inferior leads, 3-mm ST-segment elevation in anterolateral precordial leads V3 and V4, and 2-mm ST-segment elevation in V5 and V6, with right axis deviation. He was transported emergently to the cardiac catheterization laboratory where coronary angiography revealed complete occlusion of multiple anomalous branches of the right coronary system with hazy appearance suggesting the presence of thrombotic material. An aspiration catheter was used successfully to reestablish TIMI grade III flow. The patient was treated with aspirin, brilinta (ticagrelor), and anticoagulation with vitamin K antagonism to prevent recurrent thromboembolic complications.

Entities:  

Keywords:  Fontan; adult congenital heart disease; angioplasty; coronary artery anomaly; embolism; hypoplastic left heart syndrome; myocardial infarction

Mesh:

Year:  2016        PMID: 27297083     DOI: 10.1177/2150135116651860

Source DB:  PubMed          Journal:  World J Pediatr Congenit Heart Surg        ISSN: 2150-1351


  2 in total

1.  Percutaneous coronary intervention following Fontan procedure.

Authors:  Ahmed Subahi; Thomas Forbes; Omar E Ali
Journal:  Int J Cardiol Heart Vasc       Date:  2020-04-08

2.  Validation of myocardial infarction diagnosis in patients with congenital heart disease in Sweden.

Authors:  Maria Fedchenko; Zacharias Mandalenakis; Görel Hultsberg-Olsson; Helena Dellborg; Peter Eriksson; Mikael Dellborg
Journal:  BMC Cardiovasc Disord       Date:  2020-10-23       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.